¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º [ |;Zxb:  
uA/.4 b  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ C=_-p"O#  
$8T|r+<  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) Gv+Tg/  
0*:hm%g  
1. ICAM-1 ESf7b `tS  
GqD!W8+  
2. interleukin 12(IL-12) .gkPG'm[  
=5=Vm[  
3. tumor infiltrating lymphocyte -S3+ h$Y8  
tDLk ZCP  
4. TCR/CD3 complex 2=,Sz1`t  
#m$%S%s  
5. hematopoietin receptor family tD0>(41K  
w{O3P"N2  
6. individual idiotype(IdI) I~ ]mX;  
_NqT8C4C  
7. integrin N[bf.5T  
 t-x"(  
8. colony-stimulatory factor (CSF) &?Z)V-1H  
pD6g+Taj  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© +e4<z%1  
dQ|Ht[ s=  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? l}-`E@w  
ee0>B86tE  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ R}6la.mQ  
YB1DL ^ :  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠvG_v89t!ex  
 2:/MN2  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ xA'#JN<*  
jLS]^|  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) o4'4H y  
@wgGnb)  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ c%/&@vs7  
d?y\~<  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) %c/"A8{eb  
G /3lX^Z>  
3. immunoglobulin superfamily (IgSF) ];~[Olc  
Y9y*" :&%  
4. selectin i{[H 3p8  
|A/_Qe|s2  
5. anti-idiotypic antibody (¦ÁId) 35kbE'  
]%8;c  
6. major histocompatibility complex(MHC) R{A/ +7!  
f/i,Zw  
7. immunotolerance 6U9Fa=%>}  
N_[ Q.HD"  
8. biological reponse modifier(BRM) ~EkGG .  
[ \n.[4gq"  
9. immune reponse gene (Ir gene) %_O>Hy|p  
6-}e-H  
10. reshaped antibody (or reconstituted antibody) 'wV26Dm  
@@mW+16  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© T\CQ  
> 0)`uJ  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ v$/i5kcWx  
@$} \S  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? &n kGdHX/a  
<!XnUCtV  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ } U1shG[  
([o:_5/8I  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? R! xc $`N  
Ap18qp  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ UpBYL?+L  
>&Lu0oHH  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? j'cCX[i  
7O :Gi*MA  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ Ll48)P{+}V  
OZ9j3Q;a$  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ 0k]N%!U  
:b)@h|4  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? rVmO/Y#Hx$  
P ^+>QJ1  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ @cNI|T  
ueo3i1  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: )A;<'{t #L  
1h{_v!X  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: NKYyMHv6  
:7*\|2z A  
ÃâÒßѧ ^r$5];n  
|9M y>8k(  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© vUA`V\  
Zwl?*t\D  
1. CD8 FiL JF!  
< 3OV  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) EB,>k1IJ  
'KG`{K $  
3. immunoglobulin fold(Ig fold) 7 G2N&v>  
'(*D3ysU  
4. cadherin (Ca-dependent cell adhesion moleculers) YSmz)YfX9  
d~%Rnic6*  
5. idiotype-anti-idiotypic antibody immune network theory TA5M4r6  
 UI'eD)WR  
6. HLA class II antigen " OtLJ  
f}4h}Cq  
7. complementarity-determining region (CDR) -B!pg7>'##  
l.! ~t1i  
8. perforin(or pore-forming protein ,PFP) %yVZ| d*Q  
7)#/I  
9. high affinity IL-2 receptor Zup?nP2GkT  
!JA63  
10. artificial active immunization DJ .Ct4  
*lSIT]1  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 2UquN0  
V{r@D!}  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ%;S5_K,  
}sZ]SE  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 ;I0/zeM%  
:H{8j}"  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ $- L) >"  
[+GG Wo  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ g;pymz  
y[vjqfdmU  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ JkmL'Zk>:  
f]4gDmn^  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? Vz^:| qON  
lF<(yF5  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ &uM?DQ`o8  
$f%_ 4 =  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ bCsQWsj^NW  
O_033&  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ bm^ou#]|  
>9DgsA`'  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ l\eq/yg_  
lL?;?V~  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© _LK(j;6K}  
G100L}d"N  
1. immunoglobulin gene rearrangement CA3.fu3(p  
rpd3Rp  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) /{lls2ycW%  
NXV%j},>  
3. flow cytometry(FCM) 6^ ~& sA  
Z^sO`C  
4. carrier effect IL<5Suz:  
kn! J`"b  
5. positive selection of T lymphocytes in thymus PW}Yts7p  
#2pgh?  
6. mouse TH1(Th1) and TH2(Th2) subsets &B) F_EI  
-Iq#h)Q*  
7. perforin (pore-forming protein ,PFP) Ys\l[$_`*  
/HLQ  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) re<"%D  
1$c*/Tc:E  
9. SH-2(src-homology region 2) N @k:kI  
o;"!#Z 1SJ  
10. Ab2¦Â (internal image) 5ewQjwW0  
$XJe)  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© R^D~ic N  
Blu^\:?#z-  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? ==$Ox6.  
[}FP_Su$6  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? B64%| S  
aFhsRE?YC=  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠZ#9{1sHEP  
#u#s'W  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ F7mzBrz  
?L|@{RS{|  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠH>M0G L  
$)kIYM&  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) 4H{L>e  
T1D7H~ \lG  
ÃâÒßѧרҵ£º t0?\5q  
W(EU*~<UC  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ R D)dw  
%2V_%KA  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? nc([e9_9v  
 16x M?P  
´«È¾²¡Ñ§×¨Òµ£º ,)%nLc  
c_%vD~6W-  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ he 9qWL&^G  
ZcIwyh(`  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ OfIml.  
i |cSO2O+  
Ïû»¯×¨Òµ£º <.~j:GbsE  
z9E*Mh(NE  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ r*y4Vx7  
!i0:1{.  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? I9TOBn|6   
=f?|f  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ lfb]xu]O  
8q}`4wCD$  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© & Z*&&  
enE8T3   
1. Fas(CD95)/FasL 6imDA]5N&  
NgQ {'H[Y  
2. common chain of cytokine receptor t d-EB&i\  
[iB`- dE,  
3 . TCR/CD3 complex x~Y]c"'D  
tBp dKJn##  
4. negaive selection of thymocytes 5o'V}  
cea%M3  
5. artificial active immune  NDm3kMa  
fMP$o3;  
6. anti-idiotypic ldO6W7 G|h  
P]bI".A8  
7. IgSF xOp8[6Ga'  
o&-q.;MY  
8. Integrin v=RQ"iv8  
VMe~aUd  
9. chemokine E}00y%@*J  
8%@7G*  
10. B7/CD28 S8TJnv`?'  
Z4b<$t[u  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© ckHHD|  
KD11<&4_x  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ }YfM <  
nB[Aw7^|A  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ j|N;&s`  
gf$5pp-  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ sL[&y'+  
*F42GiBZR  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ 8vjaQ5  
fo;Ftf0  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ ]2`PS<a2  
{9S=:  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ 'Y Bz?l9  
Yw&{.<sL  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© kC"lO'  
kmXpj3  
1. B7/CD28 )u)]#z  
PQ9.aJdw@-  
2. Th1 subset + KGZk?%  
zkHwoAD;t8  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© J{<,V\t)  
>G(M&  
4. antibody affinity maturation w7GF,a  
_1 TSt%L  
5. AP-1 4Y2l]86  
-b'93_ZTu:  
6. single chain variable fragment£¨ScFv£© cyu)YxT  
R-CFF  
7. NK cell receptor }A)>sQ  
o_C j o  
8. Zinkernagel-Doherty phenomenon aMI\gCB/  
.b'hVOs{  
9. Ig fold I`"B<=zi  
^wDZg`  
10. CD40/CD40L lrQ +G@#  
rBG8.E36J  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© N]qX^RSb  
=73""ry  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ 57W4E{A  
9;,_Q q  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ g_{hB5N](7  
TXx%\V_6  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ &d/v/Y  
"7Qc:<ww  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ 'Y`.0T[&  
@k.j6LKbc  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ qgTN %%"~  
k8]=5C?k  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ CYlZ<W'  
XHq8p[F  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ w783e  
49S q)jd<  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© doJ\7c5uU  
-26GOS_8z  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© LeY!A# j  
OW$? 6  
1.Co-stimulators (or co-stimulating molecules) n|,kL!++.  
`a.1Af;L  
2.NK-kB X8U._/'N  
7=jeq|&kN  
3.Immunoglobulin superfamily ~ $I2{I#W  
pfCNFF*"  
4.antigen-presenting cell (APC) y~jKytq^@  
wr\d5j  
5.death domain |BysSJ  
i Rwqt-WZ  
6.CCR and CXCR U4hsbraz  
qGS]2KY  
7.Lectin (or mitogen) z` b. ~<P  
XWo=?(iA  
8.Clusters of differentiation, CD) UH8)r  
^:0NKq\  
9.B7 family 8'+XR`g:ax  
5S:&^ A<  
10.Cytotoxic T lymphocyte, CTL) w+vYD2 a  
pf.T{ /%  
11.IL-15 and IL-15 receptor (IL-15R) 22?9KZ`Z=  
/wIev1Z!Y  
12.MHC restriction _tE$a3`  
xBGSj[1`i  
13.Affinity-chromatography `m5cU*@D  
LyA=(h6  
14.Cyctosprin A, CsA ;D_6u(IC4:  
8a{FxCBw  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) `nM Huv  
Rs; ,_  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© }#@P+T:b  
>u5}5O P7  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 di6A.N5A  
F0Xv84:O  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ yS/ovd  
,)+O.Lf7&.  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ NXDV3MH=  
WPyd ^Y<  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© }/G~"&N[  
lqPRUkin  
ÃâÒßѧרҵ£º Cg 85  
ihH!"HH+  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ u7`<m.\  
0t 7yK  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ $y=sT({VVe  
n2-R[W^  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ K1z"..(2J  
Fw:s3ON9}  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) l;Zc[6   
+C\?G/  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) (m3p28Q?  
: M0L AN  
1. ADCC(antibody dependent cell-mediated cytotoxicity) txr!3-Ne'!  
zy@ #R;  
2. »·æß¾úËØ(cyclosporin) 6?}8z q[  
bz H5Lc{%  
3. KIR(killer cell inhibitory receptor) x)#k$ QU  
9L:v$4{LU  
4. HLDA(human leucocyte differentiation antigen) ]2zx}D4f  
xNxIqq<k  
5. Interleukin 18(IL-18) k1-?2kf"{  
{LJCY<IGq  
6. ÕûºÏËØ(integrin) [W{`L_"  
[Z Ea3/  
7. Fas/FasL Y<#7E;aL  
`! m+g0  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) Y/Y746I  
#3u8BLy$Q  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM)  ^r ; }6  
3L>V-RPiM  
10. Th1/Th2 N@)4H2_u \  
]iLfe&f  
11. »ùÒòÒßÃç(DNAÒßÃç) V=(4 c  
%t+V8A  
12. chemokines and chemokine receptor B0Z*YsbXL  
e1&c_"TOih  
13. ÃâÒßÄÍÊÜ , st4K;-  
*QLl jGe  
14. ¹²´Ì¼¤·Ö×Ó d G:=tf&1R  
d\Dxmb]o  
15. ËÀÍö½á¹¹Óò(death domain) 5QmF0z)wR  
i@B5B2  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) TS3 00F  
uvA}7L{UO  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? b:%>T PT  
O4$: xjs  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ9,,v 0tE  
.Uih|h  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î 3*arW|Xm  
dd4yS}yBlR  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ CtSAo\F  
PVtQ&m$y  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå XTeU 2I  
\-sD RW  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ UJ6WrO5#kB  
\*_a#4a  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) Uw)K [T  
Bq@G@Qi  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ u8[X\f  
y5R6/*;N.  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ g" M1HxlV  
C2`END;  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»